CompletedNot Applicable

Effect of Vitamin K in Critically Ill Patients

Sweden52 participantsStarted 2019-02-13

Plain-language summary

Critically ill patients with spontaneously prolonged pro-thrombin time, where administration of intravenous administration of phytomenadione (vitamin K) has been ordered by the treating physician will be identified. After signed informed consent baseline samples will be collected. Phytomenadione will be given and 24 hours after administration new blood samples will be collected. Several different advanced coagulation and vitamin K-assays will be performed before and 24 hours after vitamin K administration.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Critically ill patients at the postoperative care unit or at the intensive care unit with a prothrombin complex (PK-INR) \> 1.2 during office hours who are ordered parenteral phytomenadione 10 mg will be eligible for inclusion Exclusion Criteria: * Warfarin treatment * Treatment with novel oral anticoagulants * Hepatocellular carcinoma * Liver resection within 6 months * Known pre-existing coagulopathy

What they're measuring

Change in prothrombin complex (PK-INR)

Timeframe: Before and 24 hours after given phytomenadione

Trial details

NCT IDNCT03782025

SponsorRegion Skane

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-03-20

View on ClinicalTrials.gov More Coagulation Factor Deficiency trials